Pharvaris reported the FDA PDUFA target action date for deucrictibant IR is April 23, 2027; CREAATE part 1 topline data are expected in 1Q2027. Cash and cash equivalents were €283 million, and quarterly loss was €47.4 million.
PHVS · Pharvaris N.V. · Documents
Market Cap
$2.24B
Shares
70.79M
Volume · Nov 20
218.81K
Avg daily vol (3M)
755.25K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Nov 12
Current report
6-K
Deucrictibant FDA review targets April 23, 2027
Nov 9
Investor event
On-demand PDUFA date set for April 23rd, 2027
Pharvaris N.V. has an April 23rd, 2027 PDUFA date for on-demand treatment, plans CREATE topline data in the first quarter of next year, and expects parallel prophylaxis NDAs after collecting safety data in the first half of the 27th year.
Sep 15
Sep 9
Sep 8
Sep 8
Aug 12
Jun 26
Jun 11
May 20
May 13
May 12
May 11
Apr 2
Annual report
20-F
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Net loss 175.7M EUR
Diluted EPS -2.97 EUR
Apr 2
Jan 12
2025
Dec 3
Current report
6-K
Current report
Nov 12
Current report
6-K
Current report
Sep 8
Current report
6-K
Current report
Aug 12
Current report
6-K
Current report
Jul 24
Current report
6-K
Current report
Jul 10
Current report
6-K
Current report
Jun 27
Current report
6-K
Current report
Jun 10
Current report
6-K
Current report
May 13
Current report
6-K
Current report
Apr 7
Annual report
20-F
FY2024, ended Dec 31
Annual report for FY2024
Net loss 134.22M EUR
Diluted EPS -2.48 EUR
Apr 7
Current report
6-K
Current report
Jan 13
Current report
6-K
Current report
2024
Nov 13
Current report
6-K
Current report
Sep 25
Current report
6-K
Current report
Sep 23
Current report
6-K
Current report
Sep 5
Current report
6-K
Current report
Aug 14
Current report
6-K
Current report
Jun 28
Current report
6-K
Current report
Jun 11
Current report
6-K
Current report
Jun 4
Current report
6-K
Current report
May 8
Current report
6-K
Current report
Apr 12
Registration statement
F-3ASR
Registration statement
Apr 10
Current report
6-K
Current report
Apr 10
Annual report
20-F
FY2023, ended Dec 31
Annual report for FY2023
Net loss 100.88M EUR
Diluted EPS -2.63 EUR
Mar 6
Current report
6-K
Current report
Mar 6
Registration statement
F-3ASR
Registration statement
Feb 16
Current report
6-K
Current report
Feb 7
Current report
6-K
Current report
Jan 22
Current report
6-K
Current report
Jan 8
Current report
6-K
Current report
2023
Dec 8
Current report
6-K
Current report
Dec 6
Current report
6-K
Current report
Nov 2
Current report
6-K
Current report
Aug 7
Current report
6-K
Current report
Showing 1–50 of 94 documents
Key facts
CIK
1830487
CUSIP
N69605108
13F (30d)
150 filings
134 filers
Visit website
Investor relations